Dimethyl-{4-[5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-oxazol-2-yl]-phenyl}-amine

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: Dimethyl-{4-[5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-oxazol-2-yl]-phenyl}-amine
• 英文别名: N,N-dimethyl-4-[5-(3,4,5-trimethoxyphenyl)-4,5-dihydro-1,3-oxazol-2-yl]aniline
• 化学式: C₂₀H₂₄N₂O₄
• 分子量: 356.422
• InChiKey: QJYKAMGSDSQWLJ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  26
• 可旋转键数：
  6
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  52.5
• 氢给体数：
  0
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  4-(dimethylamino)-N-[2-hydroxy-2-(3,4,5-trimethoxyphenyl)ethyl]benzamide 在 吡啶 、 三氟甲磺酸酐 作用下， 以 氯仿 为溶剂， 反应 0.5h， 以220 mg的产率得到Dimethyl-{4-[5-(3,4,5-trimethoxy-phenyl)-4,5-dihydro-oxazol-2-yl]-phenyl}-amine
  参考文献：
  名称：

  New Antimitotic Agents with Activity in Multi-Drug-Resistant Cell Lines and in Vivo Efficacy in Murine Tumor Models

  摘要：

  During a screen for compounds that could inhibit cell proliferation, a series of new tubulin-binding compounds was identified with the discovery of oxadiazoline 1 (A-105972). This compound showed good cytotoxic activity against non-multi-drug-resistant and multi-drug-resistant cancer cell lines, but its utility in vivo was limited by a short half-life. Medicinal chemistry efforts led to the discovery of indolyloxazoline 22g (A-259745), which maintained all of the in vitro activity seen with oxadiazoline 1, but also demonstrated a better pharmacokinetic profile, and dose-dependent in vivo activity. Over a 28 day study, indolyloxazoline 22g increased the life span of tumor-implanted mice by up to a factor of 3 upon oral dosing. This compound, and others of its structural class, may prove to be useful in the development of new chemotherapeutic agents to treat human cancers.

  DOI：

  10.1021/jm010231w

文献信息

• New Antimitotic Agents with Activity in Multi-Drug-Resistant Cell Lines and in Vivo Efficacy in Murine Tumor Models
  作者：Bruce G. Szczepankiewicz、Gang Liu、Hwan-Soo Jae、Andrew S. Tasker、Indrani W. Gunawardana、Thomas W. von Geldern、Stephen L. Gwaltney、J. Ruth Wu-Wong、Laura Gehrke、William J. Chiou、R. Bruce Credo、Jeffery D. Alder、Michael A. Nukkala、Nicolette A. Zielinski、Ken Jarvis、Karl W. Mollison、David J. Frost、Joy L. Bauch、Yu Hua Hui、Akiyo K. Claiborne、Qun Li、Saul H. Rosenberg

  DOI：10.1021/jm010231w

  日期：2001.12.1

  During a screen for compounds that could inhibit cell proliferation, a series of new tubulin-binding compounds was identified with the discovery of oxadiazoline 1 (A-105972). This compound showed good cytotoxic activity against non-multi-drug-resistant and multi-drug-resistant cancer cell lines, but its utility in vivo was limited by a short half-life. Medicinal chemistry efforts led to the discovery of indolyloxazoline 22g (A-259745), which maintained all of the in vitro activity seen with oxadiazoline 1, but also demonstrated a better pharmacokinetic profile, and dose-dependent in vivo activity. Over a 28 day study, indolyloxazoline 22g increased the life span of tumor-implanted mice by up to a factor of 3 upon oral dosing. This compound, and others of its structural class, may prove to be useful in the development of new chemotherapeutic agents to treat human cancers.